Preventing lung inflammation during chemoradiation for stage III lung cancer
Treatments studied
Part of Cancer, Lungs & breathing clinical trials.
This trial tests whether two medicines, pentoxifylline and vitamin E, can help prevent a type of lung inflammation called pneumonitis in people with stage III non-small cell lung cancer who are getting chemoradiation and a checkpoint inhibitor. These medicines are already used for other conditions and may lower the risk of this side effect.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years or older.
- You have stage III non-small cell lung cancer that is planned to be treated with chemoradiation and an immunotherapy drug (checkpoint inhibitor).
- You are able to do light activities or are up and about most of the day (ECOG score 0-2).
- Your liver and kidney function tests done in the last 30 days are within safe limits.
- You are not pregnant, have not had chest radiation before, and are not allergic to pentoxifylline, caffeine, theophylline, theobromine, or vitamin E.
- You have not had a heart attack, serious heart disease, or unstable heart rhythm in the last 3 months, and you are not at risk for major bleeding.
- You can participate if you take blood thinners, but your warfarin dose will be checked often.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a combination of radiation, an immunotherapy drug called tislelizumab, and chemotherapy given before surgery for non-small cell lung cancer that has not spread too far (stage II-III). The goal is to see if this approach can shrink tumors and improve outcomes.
This trial is testing whether giving radiation therapy after surgery can help prevent lung cancer from coming back in people who have already had chemotherapy and immunotherapy before surgery. It is for patients whose cancer had spread to chest lymph nodes and who still have some cancer left in those nodes after surgery.
This trial tests a new combination of radiation therapy, an immunotherapy drug (tislelizumab), and chemotherapy to shrink bulky stage III lung cancer before possible surgery. The goal is to see if this approach is safe and effective.
This trial tests a new combination of immunotherapy and chemotherapy before and after standard chemoradiation for patients with stage III lung cancer that cannot be surgically removed. The goal is to see if this approach improves outcomes compared to chemoradiation alone.
This trial tests a combination of immunotherapy (tislelizumab), a targeted therapy (anlotinib), and standard chemotherapy before and after surgery for people with early-stage but high-risk lung cancer. The goal is to see if this treatment shrinks the tumor, makes surgery more effective, and helps prevent the cancer from coming back.
This trial tests a new schedule of chemo-radiation (fewer, stronger sessions) followed by an immunotherapy drug called tislelizumab. The goal is to see if this approach works better than the standard longer schedule for people with stage III lung cancer that can't be surgically removed.
Hear when a new Non Small Cell Lung Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.